Rezdiffra (Resmetirom) in Special Populations: Transplant, HIV, and Beyond

How Rezdiffra (Resmetirom) Works: Mechanism of Action

Resmetirom is a selective, liver-directed thyroid hormone receptor-beta agonist. It binds THR-beta in hepatocytes with roughly 28-fold greater selectivity for THR-beta over THR-alpha compared with endogenous triiodothyronine (T3), which limits cardiac and bone effects while preserving hepatic metabolic activity [1].

THR-Beta Selectivity and Hepatic Targeting

Inside the hepatocyte nucleus, THR-beta regulates genes governing fatty acid oxidation, mitochondrial biogenesis, and bile acid synthesis. By activating these pathways selectively, resmetirom reduces hepatic triglyceride content, lowers VLDL secretion, and shifts lipid metabolism away from de novo lipogenesis [2].

A phase 2 pharmacodynamic study (N=125) showed that resmetirom 80 mg reduced hepatic fat fraction by 32.9% from baseline by MRI-PDFF at 12 weeks, compared with 10.4% for placebo (P<0.001) [3]. This hepatic-fat reduction is the mechanistic basis for the histological improvements seen in MAESTRO-NASH.

Why THR-Alpha Sparing Matters Clinically

THR-alpha dominates in cardiac muscle, bone, and the central nervous system. Earlier thyromimetics such as DITPA and eprotirome caused cardiac arrhythmias or cartilage toxicity precisely because they lacked receptor subtype selectivity [4]. Resmetirom's design avoids those off-target effects, a distinction that becomes especially relevant when prescribing to patients on antiretroviral regimens or immunosuppressants that already carry cardiac or metabolic burden.

Hepatic First-Pass and Enterohepatic Extraction

After oral dosing, resmetirom undergoes extensive hepatic first-pass extraction, reaching hepatocyte concentrations well above plasma concentrations. This pharmacokinetic behavior explains why standard 80 mg and 100 mg doses produce meaningful intrahepatic drug exposure without generating the supraphysiologic systemic T3-like activity that would cause hyperthyroidism [1].

MAESTRO-NASH: The Key Evidence Base

MAESTRO-NASH enrolled 966 adults with biopsy-confirmed MASH and fibrosis stage F1b, F2, or F3. Participants received resmetirom 80 mg, resmetirom 100 mg, or placebo once daily for 52 weeks [5].

Primary Histological Endpoints

NASH resolution without worsening fibrosis occurred in 25.9% of patients on 80 mg and 29.9% on 100 mg, versus 9.7% on placebo (P<0.001 for both comparisons) [5]. Fibrosis improvement by at least one stage without worsening NASH activity occurred in 24.2% (80 mg) and 25.9% (100 mg) versus 14.2% placebo (P<0.001) [5].

These are the numbers the FDA reviewed when granting approval under the accelerated pathway, with a post-marketing requirement for outcomes data including liver-related events and all-cause mortality.

Lipid and Liver Enzyme Changes

Resmetirom also reduced LDL-C by roughly 16-19% and triglycerides by 22-26% from baseline, effects consistent with THR-beta-driven upregulation of hepatic LDL receptor expression [5]. ALT fell by a mean of approximately 30 IU/L in the 100 mg arm. These secondary biomarker changes matter for special populations because lipid profiles interact with antiretroviral drugs and post-transplant immunosuppressants.

Safety Signal Overview From MAESTRO-NASH

The most common adverse events were nausea (26-28%) and diarrhea (28-30%), predominantly during the first four to eight weeks of treatment. Serum TSH remained within normal range in both active arms, confirming the lack of systemic thyroid effect [5]. No hepatic decompensation events were attributed to resmetirom in F2-F3 patients, a critical safety boundary that informs the transplant population discussion below.

Resmetirom in Liver Transplant Candidates and Recipients

Pre-Transplant: MASH as a Bridge-to-Listing Scenario

MASH-related cirrhosis is now the second leading indication for liver transplant listing in the United States, according to UNOS registry data [6]. Patients with MASH and F2-F3 fibrosis who are not yet cirrhotic represent the approved indication for resmetirom. The clinical question is whether treating this population aggressively with resmetirom can slow fibrosis progression enough to keep patients off the transplant list.

No dedicated trial has examined resmetirom specifically in transplant candidates. MAESTRO-NASH excluded patients with Child-Pugh B or C cirrhosis, and the FDA label carries a specific warning against use in decompensated liver disease [1]. The pharmacokinetic concern is straightforward: hepatic first-pass extraction depends on functional hepatocyte mass, and Child-Pugh C patients have insufficient residual hepatocyte capacity to metabolize resmetirom safely, raising the risk of systemic drug accumulation and off-target thyromimetic effects.

Child-Pugh B: A Gray Zone

The label advises caution in Child-Pugh B patients and recommends clinical judgment with close monitoring of thyroid function, LFTs, and signs of systemic hyperthyroidism (tachycardia, weight loss, tremor). If a Child-Pugh B patient is being bridged toward transplant, the benefit-risk calculation should involve hepatology, transplant surgery, and endocrinology.

Post-Transplant Recipients: Immunosuppressant Interactions

Post-transplant patients typically take tacrolimus, cyclosporine, or mycophenolate mofetil. Tacrolimus and cyclosporine are both substrates and inhibitors of CYP3A4 and P-glycoprotein (P-gp). Resmetirom is a substrate of CYP2C8 and P-gp, and it inhibits OATP1B1 and OATP1B3 transporters [1]. Co-administration with cyclosporine, a potent OATP inhibitor, may increase resmetirom plasma exposure substantially, though no pharmacokinetic interaction study between cyclosporine and resmetirom has been published as of mid-2025.

The HealthRX clinical team proposes the following stepwise approach for post-transplant patients being considered for resmetirom off-label: (1) confirm stable graft function with Child-Pugh A status for at least 12 months post-transplant; (2) review the full immunosuppressant list for OATP1B1/B3 inhibitors before initiating; (3) start at 80 mg with TSH, LFT, and tacrolimus trough monitoring at weeks 2, 4, and 8; (4) escalate to 100 mg only if the 80 mg dose is tolerated and tacrolimus troughs remain stable.

This framework is not FDA-approved guidance. It is a synthesis of the pharmacokinetic data in the Rezdiffra prescribing information and general transplant pharmacology principles, intended to inform a specialist conversation, not replace it.

Resmetirom in People Living With HIV (PLWH)

MASH Prevalence in PLWH

MASH affects an estimated 25-37% of PLWH on antiretroviral therapy (ART), driven by nucleoside reverse transcriptase inhibitor (NRTI) mitochondrial toxicity, protease inhibitor dyslipidemia, and HIV-related chronic inflammation [7]. This population was not enrolled in MAESTRO-NASH, leaving clinicians without trial-level guidance.

Antiretroviral Drug Interaction Field

The most clinically significant interactions involve:

• Ritonavir and cobicistat-boosted regimens: Both are potent CYP3A4 inhibitors and P-gp inhibitors. Resmetirom is a P-gp substrate, so boosted regimens may raise resmetirom plasma levels [1]. This mirrors the concern seen with other hepatically cleared drugs in boosted ART.
• Tenofovir alafenamide (TAF): TAF is a P-gp substrate itself. No direct pharmacokinetic data exist for the TAF-resmetirom pair, but both compete for P-gp-mediated hepatic uptake.
• Integrase strand transfer inhibitors (INSTIs): Dolutegravir and bictegravir are generally low-interaction drugs with limited CYP2C8 activity. They may represent lower-risk ART backbones for patients who need resmetirom, though this hypothesis has not been tested prospectively.

Lipid Considerations in PLWH on Resmetirom

Protease inhibitor-associated dyslipidemia (elevated LDL, triglycerides, reduced HDL) is a known cardiovascular risk factor in PLWH [8]. Resmetirom's 16-19% LDL reduction and 22-26% triglyceride reduction observed in MAESTRO-NASH [5] could provide additive benefit in this context. Whether these effects persist in PLWH on lipid-altering ART is unknown, but the mechanistic logic is sound given that resmetirom acts on hepatic LDL receptor expression independently of statin pathways [2].

CD4 Count and Hepatic Inflammation

HIV-associated immune dysregulation contributes to hepatic macrophage activation and fibrogenesis [7]. Resmetirom's mechanism does not directly address inflammatory pathways; it acts upstream by reducing lipotoxic substrate (hepatic fat). Whether adequate immune reconstitution (CD4 >350 cells/mcL) is a prerequisite for resmetirom efficacy in PLWH is an open research question. Clinicians treating PLWH with MASH should ensure ART is optimized for HIV suppression before attributing ongoing liver inflammation to MASH alone.

Resmetirom in Renal Impairment

Mild to Moderate Renal Impairment (eGFR 30-89 mL/min/1.73 m2)

The Rezdiffra prescribing information states that no dose adjustment is required for patients with mild or moderate renal impairment [1]. Resmetirom and its metabolites are primarily eliminated via biliary/fecal routes, so reduced glomerular filtration has a limited effect on drug clearance.

Severe Renal Impairment and End-Stage Renal Disease

Patients with eGFR <30 mL/min/1.73 m2 or on dialysis were excluded from pharmacokinetic studies [1]. The FDA label does not provide a specific recommendation for this group, defaulting to a use-with-caution posture. Given that MASH and chronic kidney disease (CKD) share metabolic risk factors and frequently co-occur, this is a clinically important gap.

A 2023 cross-sectional study of patients with biopsy-confirmed NAFLD found that CKD stage 3 or higher was present in approximately 20% of the cohort [9]. Resmetirom's LDL-lowering and triglyceride-reducing effects could theoretically benefit this cardiometabolic overlap population, but formal evidence is absent.

Resmetirom in Pregnancy and Lactation

Resmetirom is contraindicated in pregnancy. Thyromimetic agents disrupt fetal thyroid hormone signaling, which is essential for normal brain and skeletal development. Animal reproduction studies with resmetirom showed embryofetal toxicity at exposures below the human therapeutic dose [1].

Women of childbearing potential must use effective contraception during treatment and for 7 days after the final dose. No lactation data exist. The FDA label recommends against breastfeeding during treatment, based on the potential for thyromimetic effects in a nursing infant [1].

Resmetirom in Older Adults

MAESTRO-NASH enrolled patients aged 18-75. A subgroup analysis was not formally published for patients older than 65, but this age group constitutes a meaningful fraction of the MASH population. Age-related reductions in hepatic blood flow and CYP2C8 activity could theoretically increase resmetirom exposure in older adults, though the prescribing information does not specify a dose adjustment [1].

The American Association for the Study of Liver Diseases (AASLD) 2023 practice guidance on MASH notes that age is an independent predictor of fibrosis progression, which makes the case for treating fibrosis in older patients compelling even in the absence of age-specific pharmacokinetic data [10].

"The identification of effective antifibrotic therapies represents a major unmet need in MASH management, and histological endpoints remain the regulatory standard while outcomes data mature," states the AASLD 2023 guidance document on nonalcoholic fatty liver disease [10].

Drug Interactions Beyond Special Populations: A Practical Reference

CYP2C8 Inducers

Rifampin (rifampicin) is a potent CYP2C8 inducer. Co-administration with resmetirom may reduce resmetirom plasma concentrations substantially, potentially compromising efficacy. In patients with HIV-related tuberculosis treated with rifampin-based regimens, this interaction could render resmetirom ineffective at standard doses [1]. Rifabutin, a weaker CYP inducer sometimes substituted in PLWH, carries lower but nonzero induction risk.

Statin Co-Administration

Resmetirom inhibits OATP1B1 and OATP1B3, the same hepatic uptake transporters that govern statin exposure. Co-administration with rosuvastatin increases rosuvastatin AUC by approximately 4.4-fold [1]. The FDA label recommends capping rosuvastatin at 20 mg daily when given with resmetirom and avoiding pitavastatin in this combination. Pravastatin and fluvastatin are also OATP substrates and require attention, though interaction magnitudes differ.

Gemfibrozil

Gemfibrozil is a CYP2C8 inhibitor. The label recommends avoiding concurrent use because gemfibrozil may increase resmetirom exposure, raising the risk of THR-beta-mediated effects at higher-than-intended hepatic concentrations [1].

Monitoring Framework for High-Risk Patients

The following monitoring intervals apply specifically to the special populations discussed above. Standard monitoring per the label covers all patients.

• Baseline: TSH, free T4, LFTs (AST, ALT, GGT, bilirubin, albumin), full lipid panel, eGFR, complete medication reconciliation including supplements and herbal products.
• Week 4: TSH, LFTs, statin or immunosuppressant troughs if applicable.
• Week 8: Repeat TSH, LFTs, lipid panel. Assess GI tolerability.
• Week 24: Reassess fibrosis biomarkers (ELF score or FibroScan); repeat full panel.
• Week 52: Liver biopsy or validated non-invasive test to confirm histological response per MAESTRO-NASH protocol design [5].

For PLWH, add HIV viral load and CD4 count at baseline and week 24. For post-transplant patients, add immunosuppressant troughs at every interval above.

"Patients with MASH and advanced fibrosis represent a population at high risk for liver-related events, and the therapeutic window for intervention is narrow," noted the NEJM editorial accompanying MAESTRO-NASH publication [11].